A method for treating or preventing a disorder or a condition by double inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a subject in need thereof, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity, comprising the step of administering to said subject a mixt...

The present invention relates to antibodies capable of binding specifically to i) the human anti-insulin/lGF-I hy-hricl receptor (hybrid-R) or ii) both to said hybrid-R and the human insulin-like growth factor I receptor (1GF-IR) and/or capable of specially inhibiting the tyrosine kinase activity of said hybrid-R or...

The present invention relates to diarylpyridazinone derivatives that block the potassium Kv channels (specifically the Kv1.5 Kv4.3 and Kv11.1 channels) and to the use thereof for the treatment of humans. Said compounds have the general formula (I) where R and R are simultaneously or independently one or more groupin...

The present invention relates to the use of levomilnacipran as a drug in functional recovery after a cerebrovascular accident or head trauma. The pharmaceutical compositions containing levomilnacipran are strictly those in which the levomilnacipran/dextromilnacipran mixture does not contain more than 5 wt % of dextr...

The present invention provides a novel isolated anti CXCR4 antibody for use in the diagnosis of cancer. In particular the antibody of the invention recognizes monomeric and homodimeric CXCR4 but not heterodimeric CXCR4

Stable pharmaceutical composition consisting of a hydrosoluble vinflunine salt and at least one diluent and one lubricant, said composition being in the form of a solid intended for oral administration. The hydrosoluble vinflunine salt is preferably Vinflunine ditartrate. The pharmaceutical composition is advantageo...

The present invention relates to the use of 3 (R) [3 (2 methoxyphenylthio) 2 (S) methylpropyl]amino 3 4 dihydro 2H 1 5 benzoxathiepine or a pharmaceutically acceptable salt thereof for treating cancer and in particular in the prevention and/or treatment of cancer metastases.

The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well as their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation.. ...

The present invention relates to an antigen binding protein in particular a monoclonal antibody capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect the invention relates to an antigen binding protein or antigen binding fragments ...

The present disclosure relates generally to anti C10orf54 antibodies including antibody drug conjugates comprising the antibodies and methods of their use.

The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antib...

The present invention relates to a docosahexaenoic acid ester including an alcohol selected from among the group made up of nicotinol panthenol inositol isosorbide and isosorbide mononitrate or one of the pharmaceutically acceptable salts enantiomers diastereoisomers or mixtures thereof including racemic mixtures fo...

The present invention claims a chromone derivative and pharmaceutical compositions and combinations comprising a least the said derivative which is a dopamine D3 receptor antagonist for their use for the treatment of autism spectrum disorder.

The present invention relates to the use of PAR1 antagonists in particular of vorapaxar of atopaxar and of 3 (2 chlorophenyl) 1 [4 (4 fluorobenzyl)piperazin 1 yl]propenone or a pharmaceutically acceptable salt thereof for preventing and/or treating pelvi perineal functional pathological conditions and more part...

The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as t...

An isolated antibody, or one of its functional divalent fragments capable of binding to the c-Met, characterized in that said isolated antibody or said functional divalent fragments is selected from: a) an antibody comprising a heavy chain comprising CDR-HI, CDR-HZ and CDR-H3 comprising respectively the amino ac...

The present disclosure relates to a novel antibody in particular a monoclonal antibody capable of binding to IGF 1R as well as the amino and nucleic acid sequences coding for said antibody.

The present disclosure relates to IGF IR (insulin like growth factor receptor 1) antibodies characterized by CDR sequences a to be used in detection methods of IGF IR expressing tumoral cells.

NA

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same a tautomer of same or a stereoisomer or mixture of stereoisomers of same in any proportions such as a mixture of enantiomers notably a racemic mixture; as well as to the use of same as a dru...

The present invention relates to an antibody drug conjugate capable of binding IGF 1R. From one aspect the invention relates to an antibody drug conjugate comprising an antibody capable of binding to IGF 1R said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins...

The present invention relates to an antibody in particular a monoclonal antibody capable of binding to IGF 1R as well as the amino and nucleic acid sequences coding for said antibody. From one aspect the invention relates to an antibody or an antigen binding fragment thereof capable of binding to IGF 1R and by induc...

The present invention concerns a compound of following formula (I) where:  R is H or OH  R is a (C C)alkyl COOH COO ((C C)alkyl) or thiazolyl group  R is H or a (C C)alkyl group and  R is an aryl (C C)alkyl group substituted by one or more groups chosen from among OH and NRR groups or a pharmaceutically acceptable s...

The invention relates to novel antibodies that can bind specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, chimeric antibodies, and humanised antibodies, and to the amino acid and nucleic acid sequences coding for said antibodies. The invention relates to the use of said anti...

The present invention relates to a novel isolated humanized antibody or the derived compounds or functional fragments of same capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly the present invention relates to hz515H7 antibodies spec...

The invention relates to a method for synthesizing 43-amino-4'-demethyl-4-desoxypodophyllotoxin of formula (1), characterized by comprising the following successive steps: a) reacting, in a pure weak acid or in a mixture consisting of acid, water and of organic solvent, without another solvent, at a temperature high...

The present invention relates to novel isolated antibodies, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and able to inhibit HIV-1 primary isolate replication in PBMC. More particularly, the present invention...

The invention relates to a method of improving the immunogenicity of an immunogen, antigen or hapten, by means of coupling with a small support peptide. More specifically, the invention relates to a method of preparing an immunogenic complex, as well as the complexes that can be obtained using one such method, and t...

The present invention relates to a novel divalent antibody capable of binding specifically to the human c Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor preferably both in a ligand dependent and in a ligand independent manner as well as the amino acid and nucleic...

The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminobeteroaryl compound, particu-larly as a medicament The present invention also comprises a pharma-ceutical composition comprising said anti' c-Met antibody and said amino-heteroaryl compound as combination products for ...

The present invention relates to a complex that includes mequitazine, a cyclodextrin, and an interaction agent wherein the rate of solubilization in water of complexed mequitazine, measured for a 2 g/1 mixture of mequitazine in water at 35 °C after 15 minutes of stirring, is greater than 50% at pH 9. The present inv...

The pharmaceutical or nutraceutical composition with sustained release of an active ingredient according to the present invention comprises at least one coated granule; said coated granule being composed of a particle that comprises said active ingredient and is coated with at least two coatings that comprise a comb...

This invention provides tumor metastasis-inhibiting monoclonal antibodies, mAb 41-2, mAb 50-6 and mAb 1A-5. The antigen recognized by mAb 50-6 and mAb 1A-5 has been identified as the PETA-3 antigen. The antigen recognized by mAb 41-2 has been identified as a novel tumor metastasis-associated antigen. Compositions an...

The fluorinated derivatives of catharanthine according to the invention respond to the general formula (I) in which: the dotted line expresses the possibility of the presence of a double bond when the substitution -X is absent or else a single bond when -X designates a substitution for a group: H, OR, NR" R", SR, or...

PROCESS FOR THE SYNTHESIS OF N-[3-[(2-METHOXYPHENYL)SULFANYL]-2- METHYLPROPYL]-3,4-DIHYDRO-2H-1,5-BENZOXATHIEPIN-3-AMINE"

The invention relates to the use of omega-3 fatty acid(s) or the marine and/or vegetable omega-3 fatty acid(s) source for preparing a drug for treating a hypercholesterolemia caused by the anti-retroviral treatment of patients infected by human immunodeficiency virus (HIV) by limiting a non-HDL fraction of circulat...

The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a parenterally-administered medicam...

The present invention relates to the use of 10-[(3R)-1- azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine as well as its pharmaceutically acceptable salts for the preparation of a drug having the particularity of treating or preventing urinary incontinence, by local and/or oral route

The present invention relates to a novel crystalline form of vinflunine, to a process for preparing it, and to its uses in the therapeutic field, in particular for treating cancer.

The invention relates to a process for the preparation of compounds of general formula (3) wherein: (a) represents a single or double bond; W represents a group CH, CH2, CHCH3/ CCH3, C(CH3)2, a group C(CH2)2 (i.e. a carbon atom carrying two methylene groups bonded to one another so as to form a spiro-cyclopropane...

The present invention relates to an orodispersible tablet comprised of, by weight: a maximum of 15% of a low-dose, therapeutically active substance; from 55% to 70% of mannitol of a particle size between 30 µm and 300 µm; at least 2% of maltodextrin; from 3.5% to 8% of croscarmellose sodium; from 10% to 20% of micro...

The present invention relates to the use of a Eucalyptus extract for preparation of a drug or a dietary supplement intended for treatment and/or prevention of affections or pathologies caused by neuromediator recapture disorder. The present invention also relates to a new enriched extract of Eucalyptus characterized...

The present invention relates to the use, as sole active ingredient, of dimethylaminoethanol (DMAE) in free form or in the form of salts or of esters and also of hydrates and solvates thereof, for the manufacture of a medicament for use in the treatment of a non-dementia mild cognitive impairment characterized by an...

The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated ei...

The invention relates to the use of a compound of formula (I) and the therapeutically-ac- ceptable salts thereof, more particularly where u = methyl, v and w = H, x = F, y = Cl, z = F, A = H or aminomethyl and the pharrnaceutically-acceptable addition salts with mineral or organic acids, for the product...

This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30 000.

The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination comprising vinflunine and trastuzumab.

The invention concerns a. method for coating powdery solid active substances characterized in that it comprises the following steps: a) providing (2; 3; 4) a mixture comprising at least one coating agent wherein is dissolved a supercritical or subcrit-ical fluid in conditions of temperature and pressure enabling sai...

The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such anti...

The present invention relates to new compounds of formula (I) and to their use as medicaments. Preferably, the said compounds are used in the preparation of a medicament or food supplement intended for the treatment and/or prevention of ailments or pathologies ensuing from a disorder of the reuptake of the following...

The present invention concerns aqueous-alcoholic, single-phase transcutaneous pharmaceutical compositions with an amount of alcohol of greater than 30% containing a steroid hormone combined with at least one penetrating agent selected from propylene glycol fatty acid esters, terpene derivatives, and mixtures thereof...

The present invention relates to the chemical stabilization of testosterone contained in self-adhesive transdermal devices by way of the association of a desiccant agent with said device within a sealing packaging. The use of a desiccant agent makes it possible to limit the chemical degradation of the testosterone t...

(EN) The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention ...

A pharmaceutical composition comprising pharmaceutically acceptable vehicle and a mixture of enantiomers of milnacipran (Z(±)-2-(aminomethyl)-N, N-diethyl-1-phenylcyclopropanecarboxamide), as well as their pharmaceutically-acceptable salts, wherein the mass/mass ratio between the (1S, 2R) enantiomer and the (1R, 2S)...

The present invention relates to compounds of general formula (I): wherein: R1 and R2, identical or different, represent: an atom of hydrogen or halogen, CN or NO2, with R1 and R2 not representing hydrogen simultaneously, m represents: 1 or 2 n represents: 0, 1, or 2 R3 represents: phenyl substituted or not by one o...

The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the f...

The present invention relates to compounds of general formula (I): wherein: R1 represents halogen, CN or NO2; R2 represents hydrogen or halogen; n represents 1 or 2; R3 represents phenyl substituted by one or more halogens or C1-C= alkyls; or a cyclohexyl; as well as the therapeutically-acceptable salts or solvents ...

A stable pharmaceutical composition comprising a water-soluble vinorelbine salt and at least one diluent and one lubricant, characterized in that it appears in a solid form intended for oral administration. The water soluble vinorelbine salt is advantageously vinorelbine ditartrate. The pharmaceutical composition ad...

The present invention describes a new process for the preparation of (poly)aminoalkylaminoacetamide compounds of epipodophyllotoxin useful for their applications in therapeutics as anticancer agents. This process comprises a step of condensation of a primary-amine-containing reactant, whose amine functions are not p...

The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to the 414H5 and 515H7 antibodies...

The present invention relates to novel chromene or thiochromene carboxamide derivatives, the preparation of same, pharmaceutical compositions of same and the use of same as dopamine D3 ligands as a medicament for central nervous system disorders.

The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the ...

The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly the invention relates to novel antibodies capable of binding specifically to the human cMet receptor as well as the amino acid and nucleic acid sequences coding for these antibodies. Th...

The present invention relates to the docosahexaenoatepanthenyl of the following formula: It also relates to a method for preparing same and to a pharmaceutical composition comprising same and to the use of same in the treatment or the prevention of cardiovascular diseases in particular atrial fibrillation. ...

The present invention concerns derivatives of heteroarylsulfonamides notably as blockers of Kv potassium channels and more particularly of channels Kv1.5 Kv4.3 or Kv11.1 their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 repr...

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same a tautomer of same or a stereoisomer or mixture of stereoisomers of same in any proportions such as a mixture of enantiomers notably a racemic mixture; for use in the treatment of pain. ...

The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamidc, or alkyl-urea or alkyl- sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent. Formula (1) wherein: - R represents hydrogen...

The present invention relates to the use of a novel isolated anti CXCR4 antibody in the diagnosis of cancer. In particular methods for diagnosing and/or prognosing an oncogenic disorder associated with CXCR4 expression are disclosed.

The invention relates to a method for the preparation of soluble molecular complexes, comprising one or more active substances which are poorly-soluble in an aqueous medium, included within one or more host molecules, characterised in comprising the following steps: (a) bringing one or more active substances into co...

The present invention concerns a compound of following formula (I): where:  Ri is H or OH ,-  R 2is a (Ci- C6)alkyl , COOH , COO -((Ci- C6)alkyl) or thiazolyl group-  R3 is H or a (Ci- C6)alkyl group , and  R is: ¦ a straight -chain or branched saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms su...

The present invention concerns aminocyclobutane derivatives in particular as antagonists of the NMDA receptors the application thereof in human therapy and method for preparing same. These compounds correspond to the general formula (1) for which:  X represents a hydrogen atom or a fluorine atom;  X2 is a hydrogen a...

The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11ß-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or an ether. R2...

The invention concerns 3,5-dioxo-(2H,4H)-l,2,4-tri-azine derivatives of general formula(I), wherein: RI and R2, identicalor different, represent a branched or linear C1-C7 alkyl or alkenyl radical, a C1-C6 alkyl radical substituted by groups such as trifluoromethyl, C5-C6 cycloalkyl, nitrile, C1...

The present application relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, 10-[(3S)-1 -azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine or 10-[(3R,3S)-1-azabicyclo[2.2.2 ]oct-3-ylmethyl]-10H-phenothiazine, or a pharmaceutically acceptable salt thereof, to prepare a drug to prevent...

The invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA from a cell capable of producing an antibody. More particularly, the invention relates to the generation of a monoclonal antibody library. The invention also relates to the ...

The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to an antibody capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for this antibody. The inve...

The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least ...

The present disclosure relates to chromone derivatives  their preparation  their pharmaceutical compositions and their application as D3 dopaminergic ligands as a medicament for disorders of the central nervous system.

Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its...

The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal...

The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such anti...

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a...

The present disclosure provides methods for modulating (e.g., preventing, inhibiting, blocking) the interaction of PSGL-1 and VISTA with agents (e.g., antibodies) that bind to PSGL-1 and/or VISTA.

The present invention provides an anti-VISTA antibody which is suitable for pharmaceutical development, as pharmaceutical compositions comprising this antibody, and methods of treating VISTA-mediated diseases.